Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 18/20 | 0.85 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21753384 | 0.92 | P2RX7 (1.00) | P2RX7P2RY12 | |
| SCHEMBL23949851 | 0.91 | P2RX7 (0.85) | P2RX7P2RY12 | |
| SCHEMBL23949853 | 0.89 | P2RX7 (0.83) | P2RX7P2RY12FLT1FLT4KDR | |
| SCHEMBL21753443 | 0.82 | P2RX7 (1.00) | P2RX7P2RY12 | |
| SCHEMBL23949980 | 0.81 | P2RX7 (0.68) | P2RX7P2RY12 | |
| SCHEMBL21753383 | 0.80 | P2RX7 (1.00) | P2RX7P2RY12TYK2 | |
| SCHEMBL23949831 | 0.79 | P2RX7 (0.66) | P2RX7P2RY12JAK2 | |
| SCHEMBL23950061 | 0.79 | P2RX7 (0.56) | P2RX7P2RY12FLT1FLT4KDR | |
| SCHEMBL31374410 | 0.78 | P2RX7 (0.72) | P2RX7P2RY12 | |
| SCHEMBL21769577 | 0.77 | P2RX7 (0.63) | P2RX7P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323910-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323910-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | P2RX1, P2RX3, P2RX5 | P2RX7 4/4885P2RY12 14/4885FLT1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.